Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An ongoing study is assessing pediatric and young adult cancers that did not respond to initial treatments.
Researchers are using multiple strategies to tackle the same problem—how to activate T cells in people who don’t respond to immunotherapy.
While her response is not average, doctors say it represents a step forward for people with diffuse midline gliomas, a rare cancer.
A set of mouse studies shows that this dietary intervention could be groundbreaking for breast cancer research.
Scientists seek to design clinical trials to test therapies that are tailored to the specific genetic drivers of rare tumors.
The Human Tumor Atlas Network initiative will create maps of human tumors and their surrounding environment.
An interview with researcher Mario Suvà, MD, PhD
Approach prevents cancers from making proteins they need to grow and to evade the immune system, while leaving healthy cells unharmed.
Cancer Research UK created a 3D model of breast cancer, giving researchers an inside view of how cancer cells interact with healthy tissue.
“No one has examined the geography of a tumor in this level of detail before,” say researchers.
Though researchers knew that exosomes play important roles in cancer and in the immune system, only now are they learning the specifics.
“It stands to reason that we should develop treatments specifically for appendix cancer.”
A common mutation makes mouse tumors more vulnerable to certain cancer drugs.
Clinical trial tests personalized treatments in push to improve pediatric cancer survival.
Researchers call the association of circulating tumor cells in blood with late recurrence of breast cancer “a really important observation.”
Scientists aim to gather knowledge that improves future immunotherapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.